Pharmacokinetic and preclinical safety studies of endolysin-based therapeutic for intravenous administration
- 6 September 2024
- journal article
- research article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 64 (5) , 107328
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Bacteriophage endolysins — extending their application to tissues and the bloodstreamCurrent Opinion in Biotechnology, 2021
- Advanced engineering of third-generation lysins and formulation strategies for clinical applicationsCritical Reviews in Microbiology, 2020
- NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand dataNucleic Acids Research, 2020
- The global preclinical antibacterial pipelineNature Reviews Microbiology, 2019
- Methylated Bovine Serum Albumin (mBSA)-Induced Delayed-Type Hypersensitivity in Mice2018
- Influence of Molecular size on the clearance of antibody fragmentsPharmaceutical Research, 2017
- Pharmacokinetics of the phage endolysin‐based candidate drug SAL200 in monkeys and its appropriate intravenous dosing periodClinical and Experimental Pharmacology and Physiology, 2016
- Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and developmentmAbs, 2015
- Non-compartmental Analysis2012
- Immunogenicity of therapeutic proteins: Clinical implications and future prospectsClinical Therapeutics, 2002